<DOC>
	<DOCNO>NCT02530060</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics ( PK ) rilpivirine/Tenofovir/Emtricitabine ( RPV/TFV/FTC ) single-oral administration Complera ( fixed-dose combination RPV , FTC , Tenefovir disoproxil fumarate [ TDF ] ) healthy Japanese adult male participant .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics Rilpivirine/Tenofovir/Emtricitabine After Single-Oral Administration Healthy Japanese Adult Male Participants</brief_title>
	<detailed_description>This single center , open-label , single oral dose study healthy Japanese adult male participant . The study consist 3 phase ; screen phase 27 day ( Day -28 Day -2 ) , in-patient phase Day -1 Day 3 ( dose day Day 1 ) , follow-up assessment phase Day 4 last follow-up assessment schedule Day 15 time early withdrawal . All participant receive single oral dose one Complera tablet Day 1 within 5 minute completion standardize breakfast . Pharmacokinetics RPV/TFV/FTC assess primary objective study . Safety participant assess throughout study .</detailed_description>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<criteria>Willing adhere prohibition restriction specify protocol Participant sexually active woman childbearing potential vasectomy must agree use barrier method birth control eg , either condom spermicidal foam/gel/film/cream/suppository partner occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository , men must also donate sperm study 3 month receive dose study drug Body mass index ( BMI ) 18 30 kilogram per meter square ( kg/m^2 ) ( inclusive ) , body weight less 50 kg Blood pressure ( participant supine 5 minute ) 90 140 millimeter mercury ( mmHg ) systolic , inclusive , high 90 mmHg diastolic Nonsmoker participant habitually smoke 10 cigarette equivalent ecigarettes , 2 cigar , 2 pipe tobacco per day least 6 month first study drug administration History current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , hepatic renal insufficiency ( creatinine clearance 60 mL/min ) , thyroid disease , neurologic psychiatric disease , infection , illness investigator considers exclude participant could interfere interpretation study result Clinically significant abnormal value hematology , clinical chemistry , urinalysis screen admission study center deem appropriate investigator Clinically significant abnormal physical examination , vital sign , 12 lead electrocardiogram ( ECG ) screen admission study center deem appropriate investigator Use prescription nonprescription medication ( include vitamin herbal supplement ) within 14 day first dose study drug schedule completion study History drug alcohol abuse accord Diagnostic Statistical Manual Mental Disorders ( 4th edition text revision 5th edition ) ( DSMIV DSM5 ) criteria International Statistical Classification Diseases Related Health Problems 10th Revision ( ICD10 ) criterion within 5 year screen positive test result ( ) alcohol and/or drug abuse ( benzodiazepine , cocaine , stimulant , cannabinoids , barbiturate , opiate , phencyclidine , tricyclic antidepressant ) screen Day 1</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Rilpivirine</keyword>
	<keyword>Tenofovir</keyword>
	<keyword>Emtricitabine</keyword>
	<keyword>Tenofovir Disoproxil Fumarate</keyword>
</DOC>